Prognosis from differentiated thyroid cancer is worse when the disease becomes refractory to radioiodine. Until recently, treatment options have been limited to local therapies such as surgery and radiotherapy, but the recent availability of systemic therapies now provides some potential for disease control. Multitargeted kinase inhibitors (TKIs) including lenvatinib and sorafenib have been shown to improve progression-free survival in phase III clinical trials, but are also associated with a spectrum of adverse effects. Other TKIs have been utilized as "redifferentiation" agents, increasing sodium iodide symporter expression in metastases and thus restoring radioiodine avidity. Some patients whose disease progresses on initial TKI therapy will still respond to a different TKI and clinical trials currently in progress will clarify the best options for such patients. As these drugs are not inexpensive, care needs to be taken to minimize not only biological but also financial toxicity. In this review, we examine the basic biology of radioiodine refractory disease and discuss optimal treatment approaches, with specific focus on choice and timing of TKI treatment. This clinical field
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| BACKGROUND
Differentiated thyroid cancer (DTC) is derived from aberrant follicular cells within the thyroid gland. It encompasses both papillary (PTC) and follicular (FTC) subtypes that make up the bulk of the prevalence (Figure 1 ). These epithelial-derived cancers are grouped together as they behave similarly despite biological differences. Follicular cells are stimulated by thyroid-stimulating hormone (TSH) to produce and secrete the thyroid hormones, thyroxine (T4) and triiodothyronine (T3).
The follicular cells have a unique machinery to take up iodine from blood and "organify" it to generate these hormones. It is this mechanism that is exploited with radioactive iodine treatment.
The incidence of thyroid cancer has increased in the past few decades. In Australia and the United Kingdom, there has been a surge in new diagnoses that is mostly-but not completely-explained by overdiagnosis. 1, 2 Cancer projection rates by the Australian Institute of Health and Welfare predict in 2020, 3435 new cases of thyroid cancer will be diagnosed every year. 3 In the UK, incidence rates for thyroid cancer are projected to rise by 74% between 2014 and 2035. 4 Irrespective of whether overdiagnosis plays a role in incidence, there are now more patients who need nuanced risk stratification of their disease. Most cases are associated with excellent prognosis: overall, the 5-year survival rate is 95.8%. 5 More reassuringly, the 5-year conditional survival, for those who have already survived 1 year after diagnosis, is 98%. 5 However, in aggressive DTC, 25% of cases will develop locally recurrent disease requiring additional treatments. 6 Distant metastases are rare on presentation but are found in 6-20% of patients in follow-up and this markedly increases the risk of cancer-specific mortality. and their interactions with cognate receptors on stromal fibroblasts appear also to be key processes mediating local progression ( Figure 2 ).
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Angiogenesis is a hallmark of many cancers, including DTC. 17 VEGF is upregulated in DTC and one of its coreceptors, NRP-2, has been implicated in metastases through enhancement of invasion and motility in thyroid cancer cells. 18, 19 Several studies have shown a correlation between VEGF receptor expression and metastasis in PTC.
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Anti-angiogenic therapies have become established as treatments for advanced DTC. 11 The fibroblast growth factor signalling pathway also drives tumoirogenesis and has been successfully targeted by inhibitors (reviewed in Ref.
20
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Mutation profiles of advanced metastatic and RAI refractory differentiated thyroid cancers show pathogenic roles for established oncogenic mutations in BRAF, RAS, PTEN and RET/PTC rearrangements.
14 BRAF V600E mutation has been associated with more aggressive disease and is clearly associated with locoregional recurrence, but not with distant metastases or death independently from other clinicopathological risk factors. 21, 22 There is significant gene expression variation between tumours with BRAF V600E that may explain the inconsistency of utilizing it as a prognostic marker. 14 Conversely, telomerase reverse transcriptase (TERT) promoter mutations specifically identify those thyroid cancers associated with disease-specific mortality and are associated with less differentiated PTCs. 14, 23 The simultaneous presence of TERT and BRAF V600E mutations confer the highest disease-specific mortality in DTC. 24, 25 There is a significantly higher prevalence of BRAF V600E in DTCs that have lost RAI avidity. In the last few decades, RAI therapy was delivered almost routinely postthyroidectomy to patients with DTC to ablate residual micrometastases. The most recent ATA guideline recommends limiting (or avoiding completely) administration of RAI to those with low-risk disease to avoid nonstochastic side effects such as sialadenitis. 8 These guidelines acknowledge that even in those with intermediate risk,
there is limited evidence of benefit from RAI, although it does facilitate the use of serum Tg as an accurate and sensitive tumour maker (in the absence of thyroglobulin antibodies). [29] [30] [31] In high-risk patients, postoperative RAI administration is used as adjuvant therapy, with observational data confirming an improvement in disease-free survival.
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Of note, there are no randomised controlled clinical trials demonstrating that RAI reduces the risk of mortality or recurrence these cohorts.
8
On diagnosis of distant metastases, RAI is usual first-line therapy followed by long-term TSH suppression. One subgroup that does particularly well with repeated RAI therapy is those patients with pulmonary micrometastases. 8 When the thyroid tumour becomes or is intrinsically refractory to RAI, the prognosis is poor. Patients with metastatic DTC that retains RAI avidity have a 10-year survival of 60%, whereas survival falls to 10% when either RAI avidity and/or responsiveness are lost.
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Hence, restoring iodine avidity is a priority in future DTC treatments. so that FDG-PET-positive disease is more likely to be refractory. 34 Radioiodine refractory disease is far more common in older patients:
those with large tumour burden and those with poorly differentiated subtypes such as tumours with Hurthle cell histology.
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RAI refractory disease is established when, in patients with appropriate TSH stimulation: (i) the iodine has never concentrated in the metastatic tissue so there is no uptake outside the thyroid bed; (ii) the tumour tissue has lost the ability to take up iodine despite being previously RAI avid; (iii) iodine can be concentrated in some metastases but not others; or (iv) metastatic disease progresses despite significant uptake of RAI. There is no demonstrated role for further RAI therapy in these patients unless their iodine refractory status can be reversed.
At times, the definition of refractory disease is ambiguous. In patient cohorts who have: (i) had a total of 600 mCi cumulative RAI dose; (ii) high FDG uptake on FDG-PET scan; (iii) aggressive DTC histology (insular or Hurthle Cell), the presence of refractory disease is suggestive rather than definitive. Some consensus statements have suggested that those patients who have an unresectable primary DTC tumour should also be included in this classification. 36 In these cases, when the definition is unclear, features including Tg doubling time 37 and radiological progression can be indicators of whether patients should be considered for disease-modulating therapy.
| LOCAL TREATMENT TARGETING RADIOIODINE REFRACTORY DISEASE
Local therapies are employed when the disease recurrence is locali In 
| SYSTEMIC THERAPIES FOR RADIOIODINE REFRACTORY DISEASE
Traditional systemic chemotherapies have poor response rates in DTC. The ratio of toxicity to benefit is low in these patients. 
| Sorafenib
The DECISION trial was a phase III trial that used sorafenib in 417 patients with radioiodine refractory disease. Results showed a 41% improvement in progression-free survival (10.8 vs 5.8 months). 
| Selumetinib
A novel approach to treat RAIRD disease is to facilitate I-131 therapy by increasing sodium iodide symporter expression on thyroid cancer cells. The MEK inhibitor, selumetinib, showed clinically meaningful increases in radioiodine uptake in patients with refractory thyroid cancer in a small pilot study. 28 This interesting approach may become a novel mechanism to enhance MEK inhibitor usage.
| Dabrafenib
A phase II study of 14 patients with BRAF V600E mutant thyroid carcinoma treated with the BRAF inhibitor dabrafenib showed a durable response with median progression-free survival of 11.3 months.
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Dabrafenib has also shown an increase in RAI uptake following administration to DTC patients via a similar mechanism to selumetinib; 60% of patients with BRAF V600E mutant radioiodine refractory DTC showed increased radioiodine uptake following a 42-day course of dabrafenib. 52 This study shows that a short treatment course may be effective. There are, however, limits on the amount of radioiodine patients can receive, even if avidity can be restored. Haematological cell line toxicities are often dose limiting. After 19 months follow-up, there was less disease progression in the treatment group with an improvement on median progression-free survival. 53 Pazopanib was studied in a phase II trial in RAI refractory DTC and showed a response rate of 49%. 54 Sunitinib shares a similar TKI inhibitory profile to lenvatinib and has also shown promise in improving the median time to progression in these cohorts. 55 Other trials and results are summarized in Table 1 below.
| Other systemic therapies

| ADVERSE EFFECTS OF KINASE THERAPIES
The therapeutic ceiling for TKI therapies is reached quickly due to toxicities. Drug-related toxicities and dose adjustments (dose interruption or reduction) were frequent in both the DECISION and SELECT trials. Most of the side effects are common to other TKIs, such as diarrhoea, fatigue, anorexia, hand-foot skin reaction and hypertension. The majority of the adverse events are mild to moderate, with severe or life-threatening toxicities occurring in <10% of cases, except for severe hand-foot skin reaction (20.3%
of sorafenib-treated patients) and severe hypertension (41.8% of lenvatinib-treated patients). These symptoms often improve with a brief treatment break and dose reduction. However, discontinuation of treatment occurred in 14.2% of lenvatinib-treated patients.
Deaths resulting from drug-related toxicities were rare (0.5% for sorafenib and 2.3% for lenvatinib). Nonetheless, approximately 65% of patients required at least one dose reduction in both trials, highlighting the poor tolerability of these TKIs at the approved starting dose. In the light of this, a postapproval FDA-mandated open-label, randomized trial with lenvatinib at starting doses of 24 mg or 18 mg is currently underway to evaluate the tolerability and efficacy of lower doses of drug (NCT02702388).
The optimal management of side effects arising from TKI treatment is essential to prevent premature or avoidable dose reduction or drug cessation. Critical to this are patient education and frequent clinical reviews, especially during the first 2 months of treatment when fortnightly clinical reviews should be considered to detect and manage early side effects. Patients should be encouraged to report any side effects as early as possible so that appropriate supportive care management can be instituted. Whenever possible, side effects should be managed with supportive management or dose interruption, before consideration is given to dose reduction.
On-target adverse effects of TKIs have also been used as surrogates to predict efficacy of treatment in other cancers. On-treatment neutropenia and hypertension are independent biomarkers of sunitinib efficacy in renal cell carcinoma. 56 It is unknown if this same characteristic is seen with lenvatinib and whether adverse events could assist with prognostication.
Financial toxicity is a non-negligible consideration in particular for the use of non-Australian PBS-subsidized therapies such as sorafenib for DTC or vandetanib for medullary thyroid cancer.
| CAN TKIS BE USED SERIALLY?
In the SELECT study, all prespecified subgroups (defined according to age, sex, race or ethnic group, prior treatment or no prior treatment with a tyrosine kinase inhibitor, geographic region, histologic subtypes, BRAF or RAS mutation status, and baseline thyrotropin levels) derived benefit from lenvatinib treatment. Therefore, prior use of TKI is not a contraindication to commencement of lenvatinib.
| TO WATCH OR TO TREAT?
Inclusion in the major TKI clinical trials required patients to have RECIST (Response Evaluation Criteria in Solid Tumours) radiologically measurable RAIR disease progression within the last 12-14 months.
Although these criteria are helpful to guide patient selection for systemic TKI treatment in routine practice, they are likely not sufficient to determine if an individual patient is a good candidate for treatment.
The biggest clinical challenge in these patients is risk stratification.
Evidence in determining who should receive systematic TKI therapy, who should be referred for local excision/EBRT and who should be closely monitored with watchful waiting is still evolving (see Table 2 ).
In Australia, lenvatinib is now available on the PBS for treatment of radioiodine refractory disease. In the UK, lenvatinib is not yet available commercially but access is through a compassionate programme on a case-by-case basis. Targeted therapies for RAIRD such as sorafenib are available from the Cancer Drug Fund.
No biomarkers have been validated to successfully determine who will respond best to lenvatinib or sorafenib. There was no predictive outcome when stratifying by BRAF or RAS mutation status in the phase III trials. 11, 50 There are some data looking at predictive response to
TKIs based on changes in levels of soluble VEGFR2 or angiopoietin-2. 57, 58 Lower baseline levels of VEGF have been associated with longer PFS but this is yet to be shown with the currently available TKIs.
| WHEN TO STOP?
Oncology doctrine is that therapy should cease when progression has occurred whilst on active treatment. However, a surge in tumour growth can occur once inhibitors of these proliferating pathways are ceased. 59 Best practice is not clear, and we recommend an individualized approach, with wariness of abrupt cessation if there is radiological disease progression, especially in the setting of minimal toxicity.
The Australian PBS approval for continuation of lenvatinib is contingent on nonprogression on the drug. Patients must have stable or responding disease according to the RECIST criteria. We recommend rescanning at 3-monthly intervals. ). Other approaches might include histone deacetylase inhibitors 62 or modulation of microRNAs.
| FUTURE DIRECTIONS
63
There are no studies with adjuvant TKI use in DTC, and very few with neoadjuvant chemotherapy. 64 As we begin to understand more about rapid tumour inhibition, this may become an option in selected populations when emerging data become available.
| CONCLUSIONS
Metastatic DTC should be carefully assessed for tumour burden and rate of progression. RAI will usually be the first-line therapy for these patients, and/or targeted local therapies. Once DTC becomes refrac- 
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